VOR, a clinical-stage biotechnology company focused on engineered hematopoietic stem cell therapy, demonstrates a permissible core business activity aligned with Islamic principles of preserving life. However, financial screening reveals challenges with high liquidity ratios exceeding key thresholds across major standards, leading to non-compliance in market cap-based assessments. The company maintains low debt and no identifiable non-permissible income, resulting in no purification requirement. Despite positive ESG factors, the stock is not included in any major Shariah indices, classifying it as NON_COMPLIANT overall. Investors may consider it under review in asset-based methodologies pending further data.